Transcription of US-19233 ------------------------- DOSAGE AND ...
{{id}} {{{paragraph}}}
Example: quiz answers
US-19233 ------------------------- DOSAGE AND ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use brilinta safely and effectively. See full prescribing information for (ticagrelor) tablets, for oral use Initial Approval: 2011 WARNING: (A) BLEEDING RISK, and (B) ASPIRIN DOSE AND brilinta EFFECTIVENESSSee full prescribing information for complete boxed RISK brilinta , like other antiplatelet agents, can cause significant, sometimes fatal bleeding. ( , ) Do not use brilinta in patients with active pathological bleeding or a history of intracranial hemorrhage.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BRILINTA safely and effectively. See full prescribing information for BRILINTA.
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: